Research programme: oral T-cell vaccines - VAXIMM

Drug Profile

Research programme: oral T-cell vaccines - VAXIMM

Alternative Names: VXM 04; VXM 06; VXM 10m; VXM 10ma

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VAXIMM
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Programmed cell death-1 ligand-1inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Sep 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR - 2017)
  • 01 Apr 2017 Pharmacodynamic, adverse events and immunogenicity data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 01 Dec 2016 Preclinical development is ongoing Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top